Cytovia Therapeutics
18851 NE 29th Ave
2nd Floor
Aventura
FL
33180
United States
Tel: (786) 591-7001
Website: http://www.cytoviatx.com/
About Cytovia Therapeutics
Additional address:
ABI-LAB
22 Strathmore Road
Natick, MA, 01760
44 articles about Cytovia Therapeutics
-
Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting
12/9/2022
Cytovia Inc.(DBA Cytovia Therapeutics, Inc.) today announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology's 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022.
-
Cytovia Therapeutics Presents New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Bispecific Antibodies at 2022 SITC Annual Meeting
11/7/2022
Cytovia Therapeutics, Inc. announced new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ bispecific antibodies.
-
Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting
10/27/2022
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its CD38-targeted Flex-NK™ cell engager antibodies at the American Society of Hematology's 64th Annual Meeting.
-
Cytovia Therapeutics To Present New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Cell Engagers at 2022 SITC Annual Meeting
10/6/2022
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ cell engager antibodies at the Society for Immunotherapy of Cancer's 37th Annual Meeting.
-
Cytovia Therapeutics Mourns the Passing of Cancer Immunotherapy Industry Leader and COO Dr. Olivier Jean-Marie Gouédard
9/6/2022
Cytovia Therapeutics, Inc. released the following statement on the passing of Olivier Gouédard, PharmD, MBA, who served as its Chief Operating Officer for the past year.
-
Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress
6/10/2022
Data supports further development of CYT-338 in relapsed/refractory multiple myeloma.
-
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
-
Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer
6/7/2022
Cytovia Therapeutics, LLC announced that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately.
-
Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress
5/18/2022
Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022.
-
Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer
5/6/2022
Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer.
-
Cytovia Holdings, a biopharma company focused on natural killer (NK) cells, merged with special purpose acquisition company (SPAC) Isleworth Healthcare Acquisition Corp. to go public.
-
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
4/27/2022
Cellectis announces that its partner Cytovia Therapeutics, LLC, a biopharmaceutical company empowering natural killer cells to fight cancer through stem cell engineering and multispecific antibodies, entered into a definitive business combination agreement with Isleworth Healthcare Acquisition Corp., a Special Purpose Acquisition Company.
-
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
-
Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK™ Cell Engagers at the 2022 AACR Annual Meeting
4/8/2022
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the American Association of Cancer Research's annual meeting in New Orleans on April 12th, 2022 is now available on both the AACR and Cytovia websites.
-
Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences
3/29/2022
Cytovia Therapeutics, Inc. announced today that its leadership team will present at the following upcoming conferences.
-
Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Multispecific Antibodies at 2022 AACR Annual Meeting
3/16/2022
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans April 8-13.
-
Cytovia Therapeutics’ Scientific Leadership to Present at Upcoming Conferences
12/8/2021
Cytovia Therapeutics, Inc. announced today that its scientific leadership will present at the following upcoming conferences: iPSC-Derived Cell Therapies Summit (Virtual Event).
-
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
10/12/2021
Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR -iNK cells derived from induced pluripotent stem cells and Flex-NK™ cell engager multifunctional antibodies, announced that Evelyn D’An has been appointed as Chief Financial Officer.
-
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
9/13/2021
Cytovia and TF Capital, a leading China-based biotech institutional investor, have formed CytoLynx Therapeutics.
-
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating OfficerKey leadership addition to accelerate operational execution of development and manufacturing
6/22/2021
Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Gouédard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately